SOURCE: Imaging Diagnostic Systems, Inc.

June 01, 2007 15:20 ET

Imaging Diagnostic Systems CEO to Be Interviewed on MN1.com on June 4 at 1:45 PM EDT

Company's Breast Imaging System for Detection of Breast Cancer and FDA Filing (PMA) to Be Discussed

FORT LAUDERDALE, FL--(Marketwire - June 1, 2007) - Imaging Diagnostic Systems, Inc. (OTCBB: IMDS), a pioneer in laser optical breast imaging systems, announced today that Mr. Timothy Hansen, CEO of Imaging Diagnostic Systems, Inc., will be interviewed live on MN1.com. Topics to be discussed will be the distinct advantages of the non-invasive, painless, non-radiation and no breast compression Computer Tomography Laser Mammography (CTLM) system. In addition, the company will address the Pre-Market Approval (PMA) clinical trials currently in process for the eventual filing with the FDA.

To learn more about Imaging Diagnostic Systems, Inc. and its investment opportunities, log on to www.mn1.com on June 4, 2007 at 1:45 PM EDT.

To be included on the company's database for company press releases and industry updates, send an e-mail to lcgroup@mindspring.com.

About Imaging Diagnostic Systems, Inc.

Imaging Diagnostic Systems, Inc. has developed a revolutionary new imaging device to aid in the detection and management of breast cancer. The CTLM® system is a breast imaging system that utilizes patented continuous wave laser technology and computer algorithms to create 3-D images of the breast. The procedure is non-invasive, painless, and does not expose the patient to ionizing radiation or painful breast compression. CT Laser Mammography (CTLM®) is designed to be used in conjunction with mammography. It reveals information about blood distribution in the breast and may visualize the process of angiogenesis, which usually accompanies tumor growth.

Imaging Diagnostic Systems is currently collecting data from clinical sites for the future filing of an FDA Premarket Approval (PMA) for the Computed Tomography Laser Mammography (CTLM®) system to be used as an adjunct to mammography. The FDA has determined that the Company's clinical study is a non-significant risk (NSR) investigational device study under 812.3(m) of the investigational device exemptions (IDE) regulation (21 CFR 812). The CTLM system is limited by United States Federal Law to investigational use only in the United States. The CTLM system has received other registrations including CE, CMDCAS Canadian License, China SFDA, UL, ISO 9001:2000, ISO 13485:2003 and FDA export certification.

About MN1.com

Market News First (MN1) is an online market news provider that delivers investors current news on the market. MN1 is the only online, live IPTV web site that brings real market news to investors and features live interaction with companies from the Bulletin Board to NYSE.

Through daily live interviews, MN1 keeps investors current on all the established companies and inform investors of the newest opportunities within the market. Market News First offers one-on-one interviews with the presidents and CFOs of companies to deliver answers to the questions that investors may ask and provides them insight into the companies' present condition and future plans.

As contemplated by the provisions of the Safe Harbor section of the Private Securities Litigation Reform Act of 1995, this news release may contain forward-looking statements pertaining to future, anticipated, or projected plans, performances and developments, as well as other statements relating to future operations. All such forward-looking statements are necessarily only estimates or predictions of future results or events and there can be no assurance that actual results or events will not materially differ from expectations. Further information on potential factors that could affect Imaging Diagnostic Systems, Inc., is included in the Company's filings with the Securities and Exchange Commission. We expressly disclaim any intent or obligation to update any forward-looking statements.

Contact Information